Johnson & Johnson to Acquire Ollin Biosciences for Up to $3.3 Billion
Article excerpt
Highlighted: the sentence this signal was extracted from
Johnson & Johnson has agreed to acquire Ollin Biosciences , a privately held clinical-stage biotechnology company developing treatments for serious retinal diseases, for $2.2 billion upfront and up to approximately $1.1 billion in additional regulatory and commercial milestone payments. The transaction, which could reach approximately $3.3 billion if all milestones are achieved, is expected to close by the end of 2026, subject to regulatory approvals and customary closing conditions. The acquisition would give Johnson & Johnson control of Ollin's lead drug candidate, OLN324, an investigational bispecific antibody currently in Phase 3 development for wet age-related macular degeneration (AMD) and diabetic macular edema. OLN324 is designed to target vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), two proteins involved in abnormal blood vessel growth and leakage in retinal diseases. The therapy is being developed with optimized molecular size and potency to potentially improve treatment outcomes. Wet AMD and diabetic macular edema collectively affect more than 40 million people worldwide and are among the leading causes of vision loss. Ollin has reported proof-of-concept clinical data suggesting OLN324 could improve retinal anatomy, although the therapy remains investigational. Founded in 2023, Ollin was established to acquire and advance ophthalmology drug...
Keep reading with a free account
The rest of this article, and every signal for Johnson & Johnson, is in your free account.
